Advanced Enzyme Technologies Profit & Loss Annual

BSE: 540025 | NSE: ADVENZYMES | ISIN: INE837H01020 | Sector: Biotechnology & Drugs

265.30 +0.30 (0.11%)Updated : 09 Oct 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	545.10	478.99	469.46	419.71
Other Net	7.35	6.09	14.17	22.93
Diluted Weighted Average Shares	11.20	11.20	11.19	11.18
Gain( Loss)on Saleof Assets	-0.10	0.23	-0.31	-0.75
Depreciation/ Amortization	40.09	36.56	35.24	35.03
Operating Income	200.66	157.92	154.41	120.93
Net Income	168.72	131.12	133.31	105.64
Income Availableto Com Excl Extra Ord	168.72	131.12	133.31	105.64
Other Operating Expenses Total	9.87	8.45	-	-
Net Income Before Taxes	232.54	187.36	187.82	140.39
Minority Interest	-4.89	-2.86	-3.65	1.77
Net Income After Taxes	173.61	133.97	136.95	103.87
Income Availableto Com Incl Extra Ord	168.72	131.12	133.31	105.64
Costof Revenue Total	250.59	202.24	199.75	180.44
Gross Profit	495.16	434.67	424.12	360.20
Interest Inc( Exp) Net- Non- Op Total	24.63	23.13	19.55	-2.72
Unusual Expense( Income)	-11.00	0.00	15.13	4.75
Diluted Net Income	168.72	131.12	133.31	105.64
DPS- Common Stock Primary Issue	1.35	5.20	5.10	1.00
Provisionfor Income Taxes	58.93	53.39	50.87	36.52
period Type	-	-	-	-
Net Income Before Extra Items	168.72	131.12	133.31	105.64
Total Revenue	745.76	636.91	623.87	540.64
period Length	12.00	12.00	12.00	12.00
Revenue	745.76	636.91	623.87	540.64
Selling/ General/ Admin Expenses Total	254.12	230.87	218.53	198.68
Diluted Normalized EPS	14.33	11.69	12.92	9.81
Research Development	1.42	0.88	0.81	0.81
Diluted EPS Excluding Extra Ord Items	15.06	11.71	11.92	9.45